BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:STX-241 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of STX-241\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06567015-2745@assetmemo.bio
DTSTAMP:20261121T005836Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:STX-241: Phase 1/2 readout est. (NCT06567015)
DESCRIPTION:STX-241\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Study
  of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EG
 FR TKIs\nEstimated primary completion: 20 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/stx-241#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06567015
URL:https://assetmemo.bio/drug/stx-241#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
